<DOC>
	<DOCNO>NCT00186940</DOCNO>
	<brief_summary>This multi-center trial rasburicase child high risk tumor lysis syndrome history asthma/atopy . The main purpose study establish safety drug patient history asthma severe allergy .</brief_summary>
	<brief_title>Rasburicase Treatment Chemotherapy Malignancy-Induced Hyperuricemia Asthma/Allergy Patients</brief_title>
	<detailed_description>Because exclude clinical trial non-recombinant urate oxidase rasburicase , safety rasburicase population know , though preliminary data indicate drug safe . The primary objective study estimate proportion grade 3 4 allergic reaction rasburicase patient history asthma severe allergy ( antigens rasburicase urate oxidase ) treat rasburicase prevention treatment malignancy chemotherapy-induced hyperuricemia . Patients risk tumor lysis syndrome history asthma/atopy treat rasburicase accord standard practice observe allergic reaction .</detailed_description>
	<mesh_term>Hyperuricemia</mesh_term>
	<mesh_term>Tumor Lysis Syndrome</mesh_term>
	<mesh_term>Rasburicase</mesh_term>
	<criteria>A diagnosis hematologic malignancy . Existing hyperuricemia high risk develop hyperuricemia malignancy . The treat clinician plan treat patient rasburicase . A patient eligible RASALL clinician already decide use rasburicase . Rasburicase give order make patient eligible nontherapeutic observational study . No prior exposure rasburicase urate oxidase . A history asthma significant allergy . Exclusion Criteria Wheezing active hypersensitivity reaction entry . Hypersensitivity Aspergillus protein .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>leukemia</keyword>
</DOC>